345 related articles for article (PubMed ID: 15930277)
1. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma.
Morris MR; Gentle D; Abdulrahman M; Maina EN; Gupta K; Banks RE; Wiesener MS; Kishida T; Yao M; Teh B; Latif F; Maher ER
Cancer Res; 2005 Jun; 65(11):4598-606. PubMed ID: 15930277
[TBL] [Abstract][Full Text] [Related]
2. An epigenetic genome-wide screen identifies SPINT2 as a novel tumor suppressor gene in pediatric medulloblastoma.
Kongkham PN; Northcott PA; Ra YS; Nakahara Y; Mainprize TG; Croul SE; Smith CA; Taylor MD; Rutka JT
Cancer Res; 2008 Dec; 68(23):9945-53. PubMed ID: 19047176
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
[TBL] [Abstract][Full Text] [Related]
4. Genetic and epigenetic control of UNC5C expression in human renal cell carcinoma.
Lv D; Zhao W; Dong D; Qian XP; Zhang Y; Tian XJ; Zhang J
Eur J Cancer; 2011 Sep; 47(13):2068-76. PubMed ID: 21600761
[TBL] [Abstract][Full Text] [Related]
5. Inactivation of BHD in sporadic renal tumors.
Khoo SK; Kahnoski K; Sugimura J; Petillo D; Chen J; Shockley K; Ludlow J; Knapp R; Giraud S; Richard S; Nordenskjöld M; Teh BT
Cancer Res; 2003 Aug; 63(15):4583-7. PubMed ID: 12907635
[TBL] [Abstract][Full Text] [Related]
6. Hepatocyte growth factor activator inhibitor types 1 and 2 are expressed by tubular epithelium in kidney and down-regulated in renal cell carcinoma.
Yamauchi M; Kataoka H; Itoh H; Seguchi T; Hasui Y; Osada Y
J Urol; 2004 Feb; 171(2 Pt 1):890-6. PubMed ID: 14713848
[TBL] [Abstract][Full Text] [Related]
7. Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma.
Furge KA; Chen J; Koeman J; Swiatek P; Dykema K; Lucin K; Kahnoski R; Yang XJ; Teh BT
Cancer Res; 2007 Apr; 67(7):3171-6. PubMed ID: 17409424
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic inactivation and tumor suppressor activity of HAI-2/SPINT2 in gastric cancer.
Dong W; Chen X; Xie J; Sun P; Wu Y
Int J Cancer; 2010 Oct; 127(7):1526-34. PubMed ID: 20063316
[TBL] [Abstract][Full Text] [Related]
9. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia.
Gunningham SP; Currie MJ; Han C; Turner K; Scott PA; Robinson BA; Harris AL; Fox SB
Cancer Res; 2001 Apr; 61(7):3206-11. PubMed ID: 11306510
[TBL] [Abstract][Full Text] [Related]
10. Up-regulation of hypoxia-inducible factor 2alpha in renal cell carcinoma associated with loss of Tsc-2 tumor suppressor gene.
Liu MY; Poellinger L; Walker CL
Cancer Res; 2003 May; 63(10):2675-80. PubMed ID: 12750296
[TBL] [Abstract][Full Text] [Related]
11. Hepatocyte growth factor activator inhibitor 2/placental bikunin (HAI-2/PB) gene is frequently hypermethylated in human hepatocellular carcinoma.
Fukai K; Yokosuka O; Chiba T; Hirasawa Y; Tada M; Imazeki F; Kataoka H; Saisho H
Cancer Res; 2003 Dec; 63(24):8674-9. PubMed ID: 14695180
[TBL] [Abstract][Full Text] [Related]
12. Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma.
Betsunoh H; Mukai S; Akiyama Y; Fukushima T; Minamiguchi N; Hasui Y; Osada Y; Kataoka H
Cancer Sci; 2007 Apr; 98(4):491-8. PubMed ID: 17309599
[TBL] [Abstract][Full Text] [Related]
13. Altered messenger RNA and protein expressions for insulin-like growth factor family members in clear cell and papillary renal cell carcinomas.
Cheung C; Vesey D; Cotterill A; Douglas M; Gobe G; Nicol D; Johnson D
Int J Urol; 2005 Jan; 12(1):17-28. PubMed ID: 15661050
[TBL] [Abstract][Full Text] [Related]
14. Topotecan (Hycamtin) responsiveness in human renal carcinoma cell lines of the clear cell and papillary types.
Ramp U; Mahotka C; Kalinski T; Ebel E; Gabbert HE; Gerharz CD
Anticancer Res; 2001; 21(5):3509-17. PubMed ID: 11848517
[TBL] [Abstract][Full Text] [Related]
15. Imprinted DLK1 is a putative tumor suppressor gene and inactivated by epimutation at the region upstream of GTL2 in human renal cell carcinoma.
Kawakami T; Chano T; Minami K; Okabe H; Okada Y; Okamoto K
Hum Mol Genet; 2006 Mar; 15(6):821-30. PubMed ID: 16439445
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic inactivation of the candidate tumor suppressor gene HOXB13 in human renal cell carcinoma.
Okuda H; Toyota M; Ishida W; Furihata M; Tsuchiya M; Kamada M; Tokino T; Shuin T
Oncogene; 2006 Mar; 25(12):1733-42. PubMed ID: 16278676
[TBL] [Abstract][Full Text] [Related]
17. [Two CpG-islands of SEMA3B gene: methylation in clear cell renal cell carcinoma].
Loginov VI; Khodyrev DS; Pronina IV; Maliukova AV; Kazubskaia TP; Ermilova VD; Gar'kavtseva RF; Zabarovskiĭ ER; Braga EA
Mol Biol (Mosk); 2009; 43(6):1088-92. PubMed ID: 20088387
[TBL] [Abstract][Full Text] [Related]
18. Germline and somatic c-met mutations in multifocal/bilateral and sporadic papillary renal carcinomas of selected patients.
Salvi A; Marchina E; Benetti A; Grigolato P; De Petro G; Barlati S
Int J Oncol; 2008 Aug; 33(2):271-6. PubMed ID: 18636147
[TBL] [Abstract][Full Text] [Related]
19. Functional significance of Wnt inhibitory factor-1 gene in kidney cancer.
Kawakami K; Hirata H; Yamamura S; Kikuno N; Saini S; Majid S; Tanaka Y; Kawamoto K; Enokida H; Nakagawa M; Dahiya R
Cancer Res; 2009 Nov; 69(22):8603-10. PubMed ID: 19887605
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of activator protein-2 isoforms in renal cell carcinoma.
Oya M; Mikami S; Mizuno R; Miyajima A; Horiguchi Y; Nakashima J; Marumo K; Mukai M; Murai M
Urology; 2004 Jul; 64(1):162-7. PubMed ID: 15245963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
